Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies (RWE-TDP-PRP)
Multicenter Real-World Evidence (RWE) Study: Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Resport Clinic, MD PhD
- 电话号码:+34 93 2778709
- 邮箱:abat@resportclinic.com
学习地点
-
-
-
A Coruña、西班牙、15009
- 招聘中
- Instituto Médico Arriaza
-
接触:
- Dr Rafael Arriaza, MD
- 电话号码:+34 981 113 030
- 邮箱:info@arriaza.es
-
Barcelona、西班牙、08023
- 招聘中
- Instituto Cugat
-
接触:
- Dr Ramón Cugat, MD PhD
- 电话号码:+34 938 34 64 50
- 邮箱:info@institutocugat.com
-
Barcelona、西班牙、08029
- 招聘中
- ReSport Clinic
-
接触:
- Dr Ferran Abat, MD PhD
- 电话号码:+34 932 77 87 09
- 邮箱:abat@resportclinic.com
-
Madrid、西班牙、28010
- 招聘中
- Ripoll y dePrado Medical Group
-
接触:
- Dra Patricia Núñez, MD
- 电话号码:+34 91 457 78 02
- 邮箱:madrid@ripollydeprado.com
-
Vitoria-Gasteiz、西班牙、01010
- 招聘中
- Hospital MIKS
-
接触:
- Dr Mikel Sanchez, MD PhD
- 邮箱:pacientes@hospitalmiks.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Clinical and/or ultrasound diagnosis of chronic tendinopathy (duration >6 weeks)
- Age >18 years
- Provision of written informed consent
- Willingness and ability to complete follow-up assessments for 12 months
Exclusion Criteria:
- Surgical treatment of the affected tendon within the previous 6 months
- Corticosteroid injection within the last month
- Systemic inflammatory disease (e.g., rheumatoid arthritis)
- Coagulopathies or ongoing anticoagulant therapy
- Complete blood count showing a platelet concentration <100 × 10⁹/L (to exclude patients with potential thrombocytopenia)
- Pregnancy or breastfeeding
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Patellar tendinopathy
Patellar tendinopathy treated with PRP
|
A minimal description of the standard PRP preparation and administration protocol will be included to document clinical variability and enable comparative analyses. Across all participating centers, the following variables will be systematically recorded: Type of PRP used (leukocyte-rich vs. leukocyte-poor), with standardized coding Preparation method (single vs. double centrifugation), including specification of the device used Injected volume Anatomical site and administration technique (ultrasound-guided whenever feasible) Number of treatment sessions and interval between sessions |
|
Achilles tendinopathy
Achilles tendinopathy treated with PRP
|
A minimal description of the standard PRP preparation and administration protocol will be included to document clinical variability and enable comparative analyses. Across all participating centers, the following variables will be systematically recorded: Type of PRP used (leukocyte-rich vs. leukocyte-poor), with standardized coding Preparation method (single vs. double centrifugation), including specification of the device used Injected volume Anatomical site and administration technique (ultrasound-guided whenever feasible) Number of treatment sessions and interval between sessions |
|
Plantar fasciosis
Plantar fasciosis treated with PRP
|
A minimal description of the standard PRP preparation and administration protocol will be included to document clinical variability and enable comparative analyses. Across all participating centers, the following variables will be systematically recorded: Type of PRP used (leukocyte-rich vs. leukocyte-poor), with standardized coding Preparation method (single vs. double centrifugation), including specification of the device used Injected volume Anatomical site and administration technique (ultrasound-guided whenever feasible) Number of treatment sessions and interval between sessions |
|
Chronic epycondylitis
Chronic epycondylitis treated with PRP
|
A minimal description of the standard PRP preparation and administration protocol will be included to document clinical variability and enable comparative analyses. Across all participating centers, the following variables will be systematically recorded: Type of PRP used (leukocyte-rich vs. leukocyte-poor), with standardized coding Preparation method (single vs. double centrifugation), including specification of the device used Injected volume Anatomical site and administration technique (ultrasound-guided whenever feasible) Number of treatment sessions and interval between sessions |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Visual Analog Scale
大体时间:From baseline up to 12 months post-treatment
|
From baseline up to 12 months post-treatment
|
|
|
VISA-P
大体时间:baseline, 1 month, 3 months, 6 months and 12 months
|
Change in pain and functional limitation assessed using the Victorian Institute of Sport Assessment-Patella (VISA-P) questionnaire.
Scores range from 0 to 100, with higher scores indicating better function and lower pain levels.
|
baseline, 1 month, 3 months, 6 months and 12 months
|
|
VISA-A
大体时间:baseline, 1 month, 3 months, 6 months and 12 months
|
The VISA-A is an eight item questionnaire measures Achilles tendon pain and function, with scores ranging from 0 to 100 (higher scores indicating better function).
|
baseline, 1 month, 3 months, 6 months and 12 months
|
|
Patient Rated Tennis Elbow Evaluation Scale
大体时间:baseline, 1 month, 3 months, 6 months and 12 months
|
The Patient-Rated Tennis Elbow Evaluation (PRTEE) is a 15-item self-report questionnaire designed to measure pain and functional disability in patients with lateral epicondylitis (tennis elbow).
It includes a 5-item pain subscale and a 10-item function subscale, providing a total score out of 100 to assess, evaluate, and monitor recovery.
|
baseline, 1 month, 3 months, 6 months and 12 months
|
|
Foot Function Index
大体时间:baseline, 1 month, 3 months, 6 months and 12 months
|
The Foot Function Index (FFI) is a 23-item, self-administered questionnaire designed to measure the impact of foot pathology on function, assessing pain, disability, and activity limitation.
It uses a 0-10 Likert scale for items within three subscales, with higher total percentages (0-100%) indicating greater, more severe pain and dysfunction.
|
baseline, 1 month, 3 months, 6 months and 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Predictive factors of response to PRP treatment
大体时间:baseline
|
Identify clinical patterns predictive of better PRP treatment response using multivariate analysis and artificial intelligence
|
baseline
|
|
Adverse events
大体时间:1 month, 3 months, 6 months, 12 months
|
Assess the incidence of local or systemic adverse events following PRP administration
|
1 month, 3 months, 6 months, 12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- RWE-TDP-20251206
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.